UNCY (STOCKS)
Unicycive Therapeutics, Inc. Common Stock
$6.250000
-0.120000 (-1.88%)
Prev close: $6.370000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Shalabh Gupta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $134.54M
- Employees
- 22
- P/E (TTM)
- -1.92
- P/B (TTM)
- 3.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.33 | $-0.57 | +0.2378 | +41.88% |
|
Jun 2025 (Q2)
|
$-0.52 | $-0.75 | +0.2348 | +31.11% |
|
Mar 2025 (Q1)
|
$-0.50 | $-1.16 | +0.6560 | +56.75% |
|
Dec 2024 (Q4)
|
$-2.60 | $-0.92 | -1.6820 | -183.22% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$1.86M |
| Operating Expenses | $31.57M |
| Research and Development | $12.19M |
| Other Operating Expenses | $19.38M |
| Operating Income/Loss | -$31.56M |
| Income/Loss From Continuing Operations After Tax | -$33.41M |
| Income/Loss From Continuing Operations Before Tax | -$33.41M |
| Net Income/Loss | -$33.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$33.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$33.47M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.60 |
| Diluted Earnings Per Share | $1.63 |
| Basic Average Shares | 75,616,455 |
| Diluted Average Shares | 91,636,811 |
| Assets | $50.61M |
| Current Assets | $50.29M |
| Noncurrent Assets | $324.00K |
| Fixed Assets | $75.00K |
| Other Non-current Assets | $249.00K |
| Liabilities | $13.13M |
| Current Liabilities | $13.13M |
| Accounts Payable | $957.00K |
| Other Current Liabilities | $12.17M |
| Noncurrent Liabilities | $0.00 |
| Equity | $37.48M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $37.48M |
| Liabilities And Equity | $50.61M |
| Net Cash Flow From Operating Activities | -$29.83M |
| Net Cash Flow From Operating Activities, Continuing | -$29.83M |
| Net Cash Flow From Investing Activities | -$46.00K |
| Net Cash Flow From Investing Activities, Continuing | -$46.00K |
| Net Cash Flow From Financing Activities | $40.23M |
| Net Cash Flow From Financing Activities, Continuing | $40.23M |
| Net Cash Flow | $10.35M |
| Net Cash Flow, Continuing | $10.35M |
| Comprehensive Income/Loss | -$33.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$33.41M |
| Other Comprehensive Income/Loss | $0.00 |